takeda pharmaceutic-sp adr (TKPYY) Key Developments
Takeda Pharmaceutical Company Introduces Zafatek in Japan
Jun 1 15
Takeda Pharmaceutical Company has introduced its Zafatek product, a once-weekly DPP-4 (dipeptidyl peptidase-IV) inhibitor, in Japan. The product is intended for the treatment of type 2 diabetes. It controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones that significantly affect blood glucose regulation. Zafatek has been approved by the Japanese Ministry of Health, Labour and Welfare based on the safety and efficacy data from multiple clinical Phase III trials in patients with type 2 diabetes in Japan.
Sanford-Burnham Partners with Takeda on Novel Treatment for Cardiovascular Disease
May 28 15
Sanford-Burnham Medical Research Institute at Lake Nona (Sanford-Burnham) announced it has signed a two-year partnership agreement with Takeda Pharmaceutical Company Ltd. to study the potential role of several gene regulatory proteins as targets for the treatment of heart failure. Based on research conducted in Sanford-Burnham laboratories, the collaborating scientists will screen and develop molecules that have the potential to improve the metabolism and function of the failing heart. This is the third research collaboration between Takeda and Sanford-Burnham over five years. As a hallmark of previously successful projects, Takeda scientists will work side by side with researchers in Sanford-Burnham's laboratories. Additionally, the collaborators will work with colleagues in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics to screen the Institute's vast library of compounds to find an effective molecule that can reactivate metabolism in heart failure patients, ultimately improving the outcome over currently available treatments.
Takeda Announces Seasonal Influenza Vaccine Sales Agreement with Kaketsuken in Japan
May 19 15
Takeda Pharmaceutical Company Limited announced that it has entered into an agreement with the Chemo-Sero-Therapeutic Research Institute (Head Office: Kumamoto City, Kumamoto Prefecture; Kaketsuken) for distribution of Kaketsukens seasonal influenza vaccine (Influenza HA Vaccine KAKETSUKEN,) in Japan, beginning in the upcoming season, 2015-2016. Takeda will continue to distribute the seasonal influenza vaccine, Influenza HA Vaccine SEIKEN, manufactured by Denka Seiken. Seasonal influenza typically occurs from early winter through early spring. Although most people quickly recover, there is a risk of progression to pneumonia, bronchitis and life-threatening severe complications, particularly in elderly individuals. As vaccination can protect against influenza infection and suppress the severity of symptoms, the Preventive Vaccination Law in Japan stipulates that the elderly are to receive regular vaccination. Given the aging population in Japan, the demand for seasonal influenza vaccine is increasing.
Takeda Pharmaceutical Company Limited Presents at FT Asia Pharma Healthcare Summit, May-20-2015 09:10 AM
May 17 15
Takeda Pharmaceutical Company Limited Presents at FT Asia Pharma Healthcare Summit, May-20-2015 09:10 AM. Venue: InterContinental, 80 Middle Road, Singapore, Singapore. Speakers: Giles Platford, President of Emerging Markets Business Unit.
Takeda Pharmaceutical Company Limited Announces Dividend for the Fiscal Year Ended March 31, 2015, Payable on June 29, 2015; Provides Dividend Guidance for the First Half 2016 and Fiscal Year Ending March 31, 2016
May 15 15
Takeda Pharmaceutical Company Limited announced a year end dividend of JPY 90.00 per share for the fiscal year ended March 31, 2015. The scheduled date of dividend payment commencement will be on June 29, 2015.
For the end of first half 2016, the company expects to pay a dividend of JPY 90.00 per share.
For the fiscal year ending March 31, 2016, the company expects to pay a dividend of JPY 90.00 per share.